Head-To-Head Contrast: Foundation Medicine (FMI) & Cellular Dynamics International (ICEL)

Foundation Medicine (NASDAQ: FMI) and Cellular Dynamics International (NASDAQ:ICEL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Foundation Medicine and Cellular Dynamics International, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foundation Medicine 0 2 3 0 2.60
Cellular Dynamics International 0 0 0 0 N/A

Foundation Medicine presently has a consensus target price of $58.25, indicating a potential downside of 22.23%. Given Foundation Medicine’s higher probable upside, analysts plainly believe Foundation Medicine is more favorable than Cellular Dynamics International.

Valuation and Earnings

This table compares Foundation Medicine and Cellular Dynamics International’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Foundation Medicine $116.86 million 23.23 -$113.19 million ($4.47) -16.76
Cellular Dynamics International N/A N/A N/A ($1.94) -8.53

Cellular Dynamics International has lower revenue, but higher earnings than Foundation Medicine. Foundation Medicine is trading at a lower price-to-earnings ratio than Cellular Dynamics International, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

30.9% of Foundation Medicine shares are owned by institutional investors. 2.7% of Foundation Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Foundation Medicine and Cellular Dynamics International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Foundation Medicine -119.69% -143.18% -93.58%
Cellular Dynamics International -88.12% -57.59% -38.09%

Foundation Medicine Company Profile

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).

Cellular Dynamics International Company Profile

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply